Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Recently launched start-up Anthos licenses Novartis' MAA868 anti-thrombotic candidate

Executive Summary

Recently launched Anthos Therapeutics Inc. in-licensed Novartis AG's MAA868, an antibody directed at clotting protein Factors XI and XIa (genetic and pharmacological components of the intrinsic coagulation pathway, which plays a role in hemostasis).
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies